5.44
price up icon0.37%   0.02
 
loading
Curevac N V stock is traded at $5.44, with a volume of 353.05K. It is up +0.37% in the last 24 hours and up +0.18% over the past month. CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
See More
Previous Close:
$5.42
Open:
$5.43
24h Volume:
353.05K
Relative Volume:
0.29
Market Cap:
$1.22B
Revenue:
$596.48M
Net Income/Loss:
$123.72M
P/E Ratio:
9.9198
EPS:
0.5484
Net Cash Flow:
$106.59M
1W Performance:
-0.73%
1M Performance:
+0.18%
6M Performance:
+64.85%
1Y Performance:
+70.53%
1-Day Range:
Value
$5.43
$5.48
1-Week Range:
Value
$5.41
$5.50
52-Week Range:
Value
$2.37
$5.72

Curevac N V Stock (CVAC) Company Profile

Name
Name
Curevac N V
Name
Phone
-
Name
Address
-
Name
Employee
1,088
Name
Twitter
Name
Next Earnings Date
2025-08-18
Name
Latest SEC Filings
Name
CVAC's Discussions on Twitter

Compare CVAC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CVAC
Curevac N V
5.44 1.23B 596.48M 123.72M 106.59M 0.5484
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Curevac N V Stock (CVAC) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-13-25 Downgrade Jefferies Buy → Hold
Apr-25-24 Downgrade Leerink Partners Outperform → Market Perform
Jun-08-23 Initiated SVB Securities Outperform
Jan-19-23 Upgrade UBS Neutral → Buy
Jan-09-23 Upgrade Jefferies Hold → Buy
Jan-21-22 Downgrade BofA Securities Neutral → Underperform
Jan-18-22 Initiated JMP Securities Mkt Outperform
Oct-22-21 Initiated Deutsche Bank Hold
Jun-17-21 Downgrade BofA Securities Buy → Neutral
Apr-26-21 Resumed Credit Suisse Underperform
Apr-26-21 Initiated Guggenheim Neutral
Dec-10-20 Downgrade Credit Suisse Neutral → Underperform
Sep-08-20 Initiated BofA Securities Buy
Sep-08-20 Initiated Credit Suisse Neutral
Sep-08-20 Initiated Jefferies Hold
View All

Curevac N V Stock (CVAC) Latest News

pulisher
Aug 19, 2025

CureVac NV earnings missed by €0.21, revenue fell short of estimates - Investing.com Australia

Aug 19, 2025
pulisher
Aug 18, 2025

CureVac: Despite weak Q2, acquisition remains on track - MarketScreener

Aug 18, 2025
pulisher
Aug 17, 2025

Is CureVac N.V. stock bottoming out2025 Trading Recap & Consistent Growth Stock Picks - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

CureVac N.V. Volume Confirms Breakout — Analysts BullishDay Trade & Expert Verified Stock Movement Alerts - classian.co.kr

Aug 17, 2025
pulisher
Aug 17, 2025

Investors Hope for Bounce in CureVac N.V. After Selloff2025 Market Trends & High Conviction Buy Zone Picks - metal.it

Aug 17, 2025
pulisher
Aug 17, 2025

Published on: 2025-08-17 02:22:48 - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

What to do if you’re stuck in CureVac N.V.2025 Year in Review & Daily Momentum Trading Reports - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Will breakout in CureVac N.V. lead to full recoveryJuly 2025 Spike Watch & Accurate Buy Signal Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

CureVac Reports Financial Losses in Mid-2025 - MSN

Aug 16, 2025
pulisher
Aug 16, 2025

Is it time to cut losses on CureVac N.V.Market Movers & Fast Entry High Yield Tips - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Is CureVac N.V. part of any ETFJuly 2025 Catalysts & Precise Buy Zone Identification - classian.co.kr

Aug 16, 2025
pulisher
Aug 16, 2025

Will CureVac N.V. price bounce be sustainableJuly 2025 WrapUp & Verified Chart Pattern Signals - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

CureVac N.V. Stages Intraday Comeback — Trend Change2025 Institutional Moves & High Accuracy Trade Signal Alerts - 선데이타임즈

Aug 16, 2025
pulisher
Aug 15, 2025

Is a relief rally coming for CureVac N.V. holders2025 Market Trends & Fast Entry Momentum Trade Alerts - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

How high can CureVac N.V. stock goWeekly Investment Report & Free Risk Controlled Daily Trade Plans - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

CureVac's Q2 Pre-Tax Loss Narrows, Revenue Falls - MarketScreener

Aug 15, 2025
pulisher
Aug 15, 2025

Earnings Flash (CVAC) CureVac Posts Q2 Revenue 1.2M Euros, vs. FactSet Est of 3.3M Euros - MarketScreener

Aug 15, 2025
pulisher
Aug 15, 2025

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates | CVAC Stock News - GuruFocus

Aug 15, 2025
pulisher
Aug 15, 2025

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates - ACCESS Newswire

Aug 15, 2025
pulisher
Aug 15, 2025

$740M Patent Settlement: CureVac Resolves Pfizer Dispute and Agrees to BioNTech Acquisition Deal - Stock Titan

Aug 15, 2025
pulisher
Aug 15, 2025

How does CureVac N.V. compare to its peersExit Point & Risk Managed Investment Strategies - thegnnews.com

Aug 15, 2025
pulisher
Aug 14, 2025

Is There Enough Volume to Lift CureVac N.V.Weekly Market Report & Free Long-Term Investment Growth Plans - newsyoung.net

Aug 14, 2025
pulisher
Aug 14, 2025

CureVac (CVAC) to Release Earnings on Thursday - Defense World

Aug 14, 2025
pulisher
Aug 12, 2025

How CureVac N.V. stock performs during market volatilityPrice Forecast Based on AI Analysis - Newser

Aug 12, 2025
pulisher
Aug 11, 2025

CureVac NV expected to post a loss of 18 cents a shareEarnings Preview - TradingView

Aug 11, 2025
pulisher
Aug 11, 2025

CureVac N.V. (NASDAQ:CVAC) Holdings Raised by Zurcher Kantonalbank Zurich Cantonalbank - Defense World

Aug 11, 2025
pulisher
Aug 11, 2025

mRNA Cancer Vaccine Market Is Going to Boom | Major Giants BioNTech, Moderna, CureVac, Gilead Sciences - newstrail.com

Aug 11, 2025
pulisher
Aug 10, 2025

Key resistance and support levels for CureVac N.V.High Return Strategy with Low Risk - Newser

Aug 10, 2025
pulisher
Aug 10, 2025

Analyzing CureVac (NASDAQ:CVAC) & ARAVIVE (NASDAQ:ARAV) - Defense World

Aug 10, 2025
pulisher
Aug 09, 2025

Can CureVac N.V. keep up with sector leadersSmart Money ROI Picks - sisain.net

Aug 09, 2025
pulisher
Aug 09, 2025

GSK set to get $500 million from settlement of mRNA lawsuit - The Economic Times

Aug 09, 2025
pulisher
Aug 08, 2025

Can a trend reversal in CureVac N.V. lead to recoverySmart Swing Picks with Confirmed Signals - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

BioNTech (BNTX) Settles mRNA Patent Dispute with CureVac for US$370 Million - Yahoo Finance

Aug 08, 2025
pulisher
Aug 08, 2025

BioNTech ends patent fight with mRNA rival CureVac ahead of buyout deal - BioPharma Dive

Aug 08, 2025
pulisher
Aug 08, 2025

Drawdown in CureVac N.V. May Be Nearing EndFast Gaining Stock Screener Reports Released - beatles.ru

Aug 08, 2025
pulisher
Aug 08, 2025

GSK Secures $370 Million In MRNA Patent Settlement Windfall - Finimize

Aug 08, 2025
pulisher
Aug 08, 2025

CureVac Enters Agreements to Resolve mRNA Patent Litigation with Pfizer/BioNTech - Contract Pharma

Aug 08, 2025
pulisher
Aug 08, 2025

CureVac announces resolution of patent litigation with Pfizer/BioNTech - Medical Dialogues

Aug 08, 2025
pulisher
Aug 08, 2025

CureVac (CVAC) Secures $740M from Patent Settlement with Pfizer and BioNTech - GuruFocus

Aug 08, 2025
pulisher
Aug 08, 2025

GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

GSK, CureVac to receive $740M as COVID vaccine patent dispute with Pfizer, BioNTech settled - Seeking Alpha

Aug 08, 2025
pulisher
Aug 08, 2025

GSK to be paid up to £370 million after patent row settles in US - uk.finance.yahoo.com

Aug 08, 2025
pulisher
Aug 08, 2025

GSK: $370m received as part of CureVac/BioNTech agreement - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

mRNA rivals call truce as BioNTech prepares CureVac takeover - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

GSK wins settlement, future royalties in CureVac mRNA patent dispute - MarketScreener

Aug 08, 2025
pulisher
Aug 08, 2025

GSK Set for $500 Million Payment From mRNA Lawsuit Settlement - Bloomberg.com

Aug 08, 2025
pulisher
Aug 08, 2025

GSK Reaches $500M Agreement Over Covid-19 Jab Patent Row - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

GSK To Get $370 Mln Upfront Payment From CureVac With MRNA Patent Settlement - Nasdaq

Aug 08, 2025
pulisher
Aug 04, 2025

Will CureVac N.V. stock benefit from AI tech trendsFast Gaining Stock Screener Reports Released - metal.it

Aug 04, 2025
pulisher
Aug 04, 2025

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth - Benzinga

Aug 04, 2025
pulisher
Aug 04, 2025

How the U.S. mRNA Therapeutics Market Will Evolve by 2032 - openPR.com

Aug 04, 2025

Curevac N V Stock (CVAC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):